<DOC>
	<DOC>NCT01532128</DOC>
	<brief_summary>The purpose of this study is to investigate the effect of BIA 9-1067 on rasagiline pharmacokinetics in healthy subjects.</brief_summary>
	<brief_title>Effect of BIA 9-1067 on Rasagiline Pharmacokinetics</brief_title>
	<detailed_description>Single-centre, open-label, randomised, three-way crossover study consisting of 3 single-dose periods separated by a washout of 14 days or more</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<mesh_term>Opicapone</mesh_term>
	<criteria>Subjects who were able and willing to give written informed consent. Male or female subjects aged between 18 and 45 years, inclusive. Subjects of body mass index (BMI) between 18.0 and 30.0 kg/m2, inclusive. Subjects who were healthy as determined by prestudy medical history, physical examination, vital signs, complete neurological examination and 12lead ECG. Subjects who had negative tests for HBsAg, antiHCVAb and HIV1 and HIV2 Ab at screening Subjects who had clinical laboratory test results clinically acceptable at screening and admission to each treatment period. Subjects who had a negative screen for alcohol and drugs of abuse at screening and admission to each treatment period. Subjects who were nonsmokers or exsmokers for at least 3 months. (If female) She was not of childbearing potential by reason of surgery or, if of childbearing potential, she used one of the following methods of contraception: double barrier or intrauterine device. (If female) She had a negative pregnancy test (Î²HCG) at screening and admission to each treatment period. Subjects who had a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular,psychiatric,musculoskeletal, genitourinary,immunological,dermatological,endocrine, connective tissue diseases or disorders. Subjects who had a clinically relevant surgical history. Subjects who had any significant abnormality in the coagulation tests. Subjects who had any significant abnormality in the liver function tests (a casebycase decision for any abnormality was to be discussed with the Sponsor before inclusion). Subjects who had a history of relevant atopy or drug hypersensitivity. Subjects who had a history of alcoholism or drug abuse. Subjects who consumed more than 14 units of alcohol a week. Subjects who had a significant infection or known inflammatory process at screening or admission to each treatment period. Subjects who had acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, heartburn) at the time of screening or admission to each treatment period. Subjects who had received fluoxetine within 5 weeks of admission to the first period. Subjects who had used any other medicines within 2 weeks of admission to first period that could affected the safety or other study assessments, in the investigator's opinion. Subjects who had previously received BIA 91067. Subjects who have used any investigational drug or participated in any clinical trial within 90 days prior to screening. Subjects who have donated or received any blood or blood products within the 3 months prior to screening. Subjects who were vegetarians, vegans or have medical dietary restrictions. Subjects who could not communicated reliably with the investigator. Subjects who were unlikely to cooperate with the requirements of the study. Subjects who were unwilling or unable to give written informed consent. (If female) She was pregnant or breastfeeding. (If female) She was of childbearing potential and she did not use an approved effective contraceptive method (doublebarrier, intrauterine device) or she uses oral contraceptives.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Parkinson Disease</keyword>
	<keyword>BIA 9-1067</keyword>
</DOC>